Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 11/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 1.00 |
| ▸ | HSPD1 | P10809 | 1/20 | 1.00 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 1.00 |
| ▸ | HSPE1 | P61604 | 1/20 | 1.00 |
| ▸ | BCHE | P06276 | 2/20 | 0.88 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.88 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.88 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.88 |
| ▸ | RELA | Q04206 | 1/20 | 0.88 |
| ▸ | F3 | P13726 | 2/20 | 0.84 |
| ▸ | XDH | P47989 | 2/20 | 0.79 |
| ▸ | MAOA | P21397 | 4/20 | 0.74 |
| ▸ | P4HB | P07237 | 1/20 | 0.74 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.74 |
| ▸ | RAB9A | P51151 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 4'-Methoxychalcone SCHEMBL521905 | 1.00 | MAOB (1.00) | MAOBMAPTMEN1ALDH1A1KMT2A | |
| 4'-Methoxychalcone SCHEMBL3698831 | 0.98 | MAOB (0.97) | MAOBMAPTMEN1ALDH1A1KMT2A | |
| 4'-Methoxychalcone SCHEMBL3698834 | 0.98 | MAOB (0.97) | MAOBMAPTMEN1ALDH1A1KMT2A | |
| 4-Methoxy Chalcone SCHEMBL1566431 | 0.93 | BCHE (1.00) | MAOBMAPTMEN1ALDH1A1KMT2A | |
| 4-Methoxy Chalcone SCHEMBL9338705 | 0.93 | BCHE (1.00) | MAOBMAPTMEN1ALDH1A1KMT2A | |
| 4-Methoxy Chalcone SCHEMBL521906 | 0.93 | BCHE (1.00) | MAOBMAPTMEN1ALDH1A1KMT2A | |
| 4,4'-Dimethoxychalcone SCHEMBL978243 | 0.91 | F3 (1.00) | MAOBMAPTMEN1ALDH1A1KMT2A | |
| 4,4'-Dimethoxychalcone SCHEMBL978242 | 0.91 | F3 (1.00) | MAOBMAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL18972861 | 0.91 | BCHE (0.88) | MAOBMAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL5887854 | 0.89 | MAOB (0.80) | MAOBMAPTMEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119823729-A | Composition for preparing cooling liquid, preparation method and application thereof | 张家港迪克汽车化学品有限公司 | 2025-04-15 | — | — | CN | claimed |
| CN-119192224-A | Alpha, beta-unsaturated ketone cyano silanization method and application | 哈尔滨理工大学 | 2024-12-27 | — | — | CN | claimed |
| US-20230293565-A1 | USE OF WNT/BETA-CATENIN PATHWAY INHIBITORS TO BLOCK REPLICATION OF SARS-COV-2 AND OTHER PATHOGENIC VIRUSES | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2023-09-21 | — | — | US | claimed |
| CN-116249520-A | Blocking replication of SARS-COV-2 and other pathogenic viruses using WNT/beta-catenin pathway inhibitors | 阿尔伯塔大学理事会 | 2023-06-09 | — | — | CN | claimed |
| EP-4188378-A1 | USE OF WNT/BETA-CATENIN PATHWAY INHIBITORS TO BLOCK REPLICATION OF SARS-COV-2 AND OTHER PATHOGENIC VIRUSES | The Governors of the University of Alberta (CA) | 2023-06-07 | — | — | EP | claimed |
| US-20230003721-A1 | MITOTHERAPEUTICS FOR THE TREATMENT OF BRAIN DISORDERS | THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2023-01-05 | — | — | US | claimed |
| WO-2022020967-A1 | USE OF WNT/BETA-CATENIN PATHWAY INHIBITORS TO BLOCK REPLICATION OF SARS-COV-2 AND OTHER PATHOGENIC VIRUSES | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2022-02-03 | — | — | WO | claimed |
| CN-111960994-A | Polarity-sensitive triphenylpyridinium fluorescent probe and preparation and application thereof | 深圳大学 | 2020-11-20 | — | — | CN | claimed |
| CN-111233645-A | Method for preparing tri-substituted cyclopentene by MBH/Wittig domino reaction of vinylon insertion | 浙江大学 | 2020-06-05 | — | — | CN | claimed |
| EP-2712367-B1 | DIRECT TRIFLUOROMETHYLATIONS USING TRIFLUOROMETHANE | UNIV SOUTHERN CALIFORNIA (US) | 2018-09-26 | — | — | EP | claimed |
| US-20140066640-A1 | DIRECT TRIFLUOROMETHYLATIONS USING TRIFLUOROMETHANE | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2014-03-06 | — | — | US | claimed |
| US-8618077-B2 | Compositions and methods for treating fragile X premutation RVGG repeats-mediated toxicity | EMORY UNIVERSITY (US) | 2013-12-31 | — | — | US | claimed |
| US-20130245070-A1 | COMPOUNDS FOR ENHANCING ARGINASE ACTIVITY AND METHODS OF USING SAME | THE RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) | 2013-09-19 | — | — | US | claimed |
| EP-1450777-B1 | PHARMACEUTICAL COMPOSITION CONTAINING CHALCONE OR ITS DERIVATIVES FOR MATRIX METALLOPROTEINASE INHIBITORY ACTIVITY | ANGIOLAB INC (KR) | 2013-05-08 | — | — | EP | claimed |
| US-20090253782-A1 | Compounds for Enhancing Arginase Activity and Methods of USe Thereof | CORNELL RESEARCH FOUNDATION, INC. | 2009-10-08 | — | — | US | claimed |
| US-7572831-B2 | Composition containing chalcone | ANGIOLAB, INC. (KR) | 2009-08-11 | — | — | US | claimed |
| WO-2008011083-A2 | COMPOUNDS FOR ENHANCING ARGINASE ACTIVITY AND METHODS OF USE THEREOF | CORNELL RESEARCH FOUNDATION, INC. (US) | 2008-01-24 | — | — | WO | claimed |
| US-20040209952-A1 | Composition containing chalcone | ANGIOLAB, INC. (KR) | 2004-10-21 | — | — | US | claimed |
| EP-1450777-A1 | PHARMACEUTICAL COMPOSITION CONTAINING CHALCONE OR ITS DERIVATIVES FOR MATRIX METALLOPROTEINASE INHIBITORY ACTIVITY | Angiolab Inc. (KR) | 2004-09-01 | — | — | EP | claimed |
| WO-2003037315-A1 | PHARMACEUTICAL COMPOSITION CONTAINING CHALCONE OR ITS DERIVATIVES FOR MATRIX METALLOPROTEINASE INHIBITORY ACTIVITY | ANGIOLAB INC. (KR) | 2003-05-08 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066640-A1 | DIRECT TRIFLUOROMETHYLATIONS USING TRIFLUOROMETHANE | TST, FLI1, CYP2F1 | MAOB 2391/4885MAPT 3128/4885MEN1 3176/4885 |
| US-20130245070-A1 | COMPOUNDS FOR ENHANCING ARGINASE ACTIVITY AND METHODS OF USING SAME | ARG2, ARG1, OTC | MAOB 172/4885MAPT 3632/4885MEN1 3845/4885 |
| US-20090253782-A1 | Compounds for Enhancing Arginase Activity and Methods of USe Thereof | ARG2, ARG1, OTC | MAOB 127/4885MAPT 3726/4885MEN1 3962/4885 |
| US-20040209952-A1 | Composition containing chalcone | MMP25, MMP13, MMP17 | MAOB 397/4885MAPT 3081/4885MEN1 3451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.